VITA 34 Valuation
Is V3V undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of V3V when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: V3V (€4.3) is trading below our estimate of fair value (€10.67)
Significantly Below Fair Value: V3V is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for V3V?
Key metric: As V3V is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is V3V's PS Ratio? | |
|---|---|
| PS Ratio | 1x |
| Sales | €78.82m |
| Market Cap | €73.91m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | 19.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does V3V's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
LIK LIMES Schlosskliniken | 2.4x | 17.7% | €100.3m |
HAEK HAEMATO | 0.3x | n/a | €72.1m |
SYAB SYNLAB | 1x | 4.4% | €2.5b |
MED MEDICLIN | 0.2x | 0.7% | €123.5m |
V3V VITA 34 | 1x | 3.1% | €73.9m |
Price-To-Sales vs Peers: V3V is expensive based on its Price-To-Sales Ratio (1x) compared to the peer average (1x).
Price to Sales Ratio vs Industry
How does V3V's PS Ratio compare vs other companies in the DE Healthcare Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
TLIK Arzneiwerk VIDA | 0.08x | n/a | US$4.76m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: V3V is expensive based on its Price-To-Sales Ratio (1x) compared to the European Healthcare industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is V3V's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1x |
| Fair PS Ratio | 0.5x |
Price-To-Sales vs Fair Ratio: V3V is expensive based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Ship Healthcare Holdings
JP¥196.5b
Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.
5EZ
JP¥12.40
7D
-3.1%
1Y
-4.6%
Sensus Healthcare
US$125.2m
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
5TX
US$7.25
7D
16.0%
1Y
272.6%
CVS Health
US$66.9b
Provides health solutions in the United States.
CVS
US$53.25
7D
2.4%
1Y
-14.7%